Bard Announces Retirement of Todd C. Schermerhorn, Senior Vice President and Chief Financial Officer

Bard Announces Retirement of Todd C. Schermerhorn, Senior Vice President and Chief Financial Officer
MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced that Todd C. Schermerhorn, senior vice president and chief financial officer, will retire after a transition period that is expected to run through August 2012. Mr. Schermerhorn will continue to serve as CFO during this period until his successor is elected.

Mr. Schermerhorn joined Bard in 1985 as a financial analyst. Over the past 26 years he has served the company in numerous financial management positions, including controller of the vascular systems division, vice president and controller of the USCI division, vice president and group controller-cardiology, and vice president and treasurer. Mr. Schermerhorn was promoted to his current position in April 2003.

Timothy M. Ring, chairman and chief executive officer, commented, "Todd's leadership has been invaluable to Bard in shaping our strategy and culture. His tireless commitment and passion for excellence has influenced our organization across every function and at every level. His business intelligence and market insights have been a direct benefit to Bard and to me personally. We wish Todd the very best in retirement."

C. R. Bard, Inc. (, headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.